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Objective: To describe the use of CNS drugs and to identify the most frequently observed potential 
drug interactions in the elderly living in Southern Brazil. Methods: A population-based, transversal and 
observational study was carried out during 2006-2007. Four hundred and eighty elderly individuals of 
both genders were randomly recruited and interviewed. A validated pharmacotherapeutic questionnaire 
and the Micromedex® Healthcare Series were utilized to analyze potential drug interactions. A severity 
rating scale employing the categories of “mild”, “moderate” and “severe” was used to describe the 
interactions. Results: A population of elderly living in Southern Brazil was interviewed and 98 reported 
using CNS drugs, 74.5% female and 25.5% male. Out of these patients, 32.0% reported severe or moderate 
pharmacological interactions related to the use of other drugs. Alprazolam and imipramine were reported 
to potentially interact with tobacco. Twenty potential moderate drug/ethanol interactions were found. 
The potential drug/caffeine interactions were classified as mild on the severity scale. Conclusion: Elderly 
being prescribed drugs that act on the CNS should be closely monitored, and furthermore, should be 
warned against potential drug-drug, drug-ethanol, and drug-tobacco interactions.
Uniterms: Elderly. Drug-Drug interactions. Central nervous system. Tobacco. Ethanol.
Objetivo: Descrever o uso de medicamentos que atuam no sistema nervoso central (SNC) e identificar 
as possíveis interações mais frequentes com esses medicamentos em idosos do sul do Brasil. Métodos: 
Estudo de base populacional, transversal e observacional, realizado durante 2006-2007. Quatrocentos e 
oitenta idosos de ambos os sexos foram randomizados e entrevistados. Foram utilizados um questionário 
farmacoterapêutico validado e o programa Micromedex® Healthcare Series para analisar as potenciais 
interações com os medicamentos. Foi utilizada uma escala para descrever a gravidade das interações nas 
categorias de “leve”, “moderada” e “grave”. Resultados: A população idosa, moradora do sul do Brasil, que 
utilizava medicamentos para o SNC, era formada por 98 pacientes, 75,5% mulheres e 25,5% homens. Destes 
pacientes, 32,0% apresentaram interações farmacológicas graves ou moderadas relacionadas com a utilização 
de outros medicamentos. Alprazolam e Imipramina, usados pela população, apresentaram riscos de potenciais 
interações com tabaco. Foram encontradas vinte potenciais interações moderadas medicamento/etanol. As 
potenciais interações medicamento/cafeína foram classificadas como leves. Conclusão: Os pacientes idosos 
deveriam ser rigorosamente monitorizados, e ainda, é necessário advertir quanto às potenciais interações 
de medicamentos que atuam no SNC com outros medicamentos, etanol e tabaco.
Unitermos: Idosos. Interações medicamento-medicamento. Sistema nervoso central. Tabaco. Etanol. 
INTRODUCTION
The mean age of the world’s population is increasing 
and this phenomenon is leading to increased demands on 
the public health system and on medical and social servi-
ces. The increased proportion of older adults has raised the 
number of hospital admissions, leading to longer hospital 
stays and a greater need for ambulatory services (Nordberg 
et al., 2007).
Aging is a major risk factor for chronic diseases 
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(Chen, Dewey, Avery, 2001) and the enlarged elderly 
population increases the prevalence of many central ner-
vous system (CNS) disorders, such as Alzheimer disease, 
stroke, and Parkinson’s disease, as well as depression, 
anxiety, and insomnia. Such disorders affect older adults 
disproportionately, and contribute to disability, a decreased 
quality of life, and increased healthcare costs. 
The elderly are the predominant users of pharma-
ceuticals in the population and inappropriate prescribing 
of medication is a concern since it increases the risk of 
drug-related problems (Paulino et al., 2004). Additionally, 
elderly patients often require multiple drugs and it is well 
documented that polypharmacy has a greater potential to 
lead to drug interactions and adverse events (Evans et al., 
2003; Frankfort et al., 2006). Furthermore, because of age-
related changes in pharmacodynamic and pharmacokinetic 
parameters, elderly patients are more likely to experience 
adverse effects from CNS agents than younger patients 
(Mort, Aparasu, 2002). 
In this regard, physiological changes, such as decre-
ased renal function and hepatic metabolism and mental im-
pairment make the elderly more vulnerable to drug-related 
problems (Woodhouse et al., 1988). Many other factors 
can also contribute to changes in the drug response, such 
as the complexity of the brain, the liability of CNS drugs 
to cause side effects, and the requirement of CNS drugs to 
cross the blood-brain barrier (Higashi et al., 2004). 
Drug interactions, such as drug-drug, drug-food, and 
drug-tobacco are considered another important risk factor 
for health problems in elderly (Keegan, Brown, Rabinstein, 
2006). Recently published studies have demonstrated that 
the use of drugs, polypharmacy and potential drug-drug 
interactions (DDIs) have increased during the last several 
years among patients, representing potential health hazards 
for the elderly (Astrand et al., 2007; Haider et al., 2007; Jo-
hnell, Klarin, 2007). According to these studies, there seems 
to be a strong relationship between the number of dispensed 
drugs and potentially serious DDIs, and the pronounced 
increase in polypharmacy over time serves as an excellent 
reason for prescribers and pharmacists to be aware of drug 
interactions (Astrand et al., 2007; Johnell, Klarin, 2007). 
Considering the prevalent use of psychotropic me-
dications in elderly patients, this study aims to describe 
the use of CNS drugs and to identify the potential drug 
interactions most frequently observed in elderly living in 
Southern Brazil. 
METHODS
A population-based, transversal and observational 
study was carried out during the months of January 2006 
until May 2007. A qualitative and quantitative drug utili-
zation study was also performed. 
The elderly interviewed were randomly recruited, by 
the University social service professionals, from different 
socioeconomic groups as previously described by Faggiani 
et al., 2007. Briefly, Porto Alegre City Hall provided the 
data for different neighborhoods where elderly citizens are 
concentrated within the population, as well as the names 
and addresses of these individuals. The sample size for this 
study was similar to the number of elderly analyzed in a 
previously published study (Rio Grande do Sul, 1996) for 
each neighborhood of Porto Alegre and was updated ac-
cording to an estimate of the population variation through 
2005 developed by the Instituto Brasileiro de Geografia e 
Estatística - IBGE (IBGE, 2003). Four hundred and eighty 
elderly individuals of both genders were interviewed. For 
the sample size calculation, it was assumed a percentage 
of 0.69% to obtain a confidence interval of 99%.
To participate in this research study, the following 
inclusion criteria were used: individuals were able-bodied 
(to allow for travel to the interview site) and were older 
than sixty years old. The elderly who refused to participate 
in the study were excluded.
Trained interviewers conducted the interviews. A 
previously validated pharmacotherapeutic questionnaire 
containing the patient’s general lifestyle information (age, 
habits and alcohol intake), disease, therapy regimens 
and information about the prescribed and utilized drugs 
was used to document the responses. The questions were 
open-ended and were answered based on the memory of 
the patient and/or using materials supplied to the patient, 
such as prescriptions and/or a label.
The Anatomical Therapeutic and Chemical Classi-
fication System (ATC) (WHO, 2004) was used to classify 
the drugs that the elderly reported using and the Micro-
medex® Healthcare Series was used to analyze the inte-
ractions (Klasco, 2005). A severity rating scale employing 
the categories of “mild” interaction (risk of adverse ou-
tcomes appears small), “moderate” interaction (to avoid 
administration unless it is determined that the benefit of 
co-administration outweighs the risk to the patient), and 
“severe” interaction (to avoid administration of combina-
tion) was used to describe the potential drug interactions.
After the data were collected, the results were kept 
in the individual’s patient file together with the comple-
ted questionnaires. The data were analyzed and tabulated 
using the computer program, SPSS version 11.5, and the 
results were presented as a percentage of the data set. 
Ninety-five percent confidence intervals (95% CI) were 
utilized to show difference in the patient’s characteristics 
(Zar, 1999). 
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The PUCRS Institutional Ethics Committee appro-
ved this study (protocol number 0502935) and the study 
participants signed the consent form.
RESULTS
In this study, a population of elderly individuals 
provided information on their use of central nervous sys-
tem drugs, and these informational data were analyzed 
to determine potential drug interactions that were being 
experienced within this population. Out of the 480 elderly 
interviewed, 64.0% used cardiovascular system drugs, 
35.0% used analgesic/anti-inflammatory drugs, and 20.5% 
of the elderly used drugs that predominantly act on the 
CNS.
Preliminarily, we gathered general information 
and lifestyle habits of the population. Table I shows that 
the majority of elderly population who used CNS drugs 
were female (74.5%). The mean age of the population 
was 72.0 (SD=6.3) for men and 73.5 (SD=6.5) for women 
and the average number of medications used by each 
patient was 2.6 (SD=2.2) for men and 3.8 (SD=2.6) for 
women. According to our data, elderly men consumed 
more alcohol (56.0%) and tobacco (24.0 %) than women 
did. These results lead us to also investigate the potential 
interactions of the prescribed CNS drugs with ethanol 
and/or tobacco use.
Figure 1A shows the predominant psychiatric patho-
logies diagnosed among the studied population. 
In our elderly sample population (480), 20.5% used 
a total of 146 CNS drugs. Amongst these, the most used 
were antidepressants, followed by anxiolytic/hypnotic, 
anticonvulsant/antiepileptic and antipsychotic/neuroleptic 
(Figure 1B).
Given that many elderly patients were prescribed 
and used CNS-acting drugs, we next wanted to evaluate 
in-depth any potential pharmacological interactions of 
the CNS drugs these patients could be experiencing. We 
found 125 potential drug interactions. These interactions 
predominantly occurred between drug-drug, drug-ethanol, 
and drug–tobacco, but we also investigated drug-caffeine 
interactions, since some of the interviewed population 
typically took their medications with coffee. 
As reported at Table II, we determined that 40 
(32.0%) of the potential DDIs were either severe or 
moderate on the severity scale. Among these, we iden-
tified the contraindication for use of amitriptyline and 
tranylcypromine (parnate®) in one patient, which can lead 
to neurotoxicity and serotonin syndrome. We found five 
severe drug interactions, most of them related to the use 
of amitriptyline together with other CNS drugs, leading to 
severe effects such as cardiotoxicity, tricyclic antidepres-
sant toxicity, respiratory depression and, in some cases, a 
subtherapeutic effect. The other drug interactions reported 
at Table II are considered of moderate severity, which lead 
to an increased risk of psychomotor impairment and seda-
tion, psychomotor deficits, increased risk of bleeding, and 
peripheral ischemia, among others. The minor interactions 
TABLE I - Characteristics of the elderly population using CNS 
acting drugs (n=98)
Men Women
n=25 
[25.5%] 
[95%CI] n=73 
[74.5%] 
[95%CI]
Age 
average
72.6 ± 6.3 73.5 ± 6.5
Drugs 
average
2.6 ± 2.2 3.8 ± 2.6
Tobacco use n=6 
[24.0%] [9.4 - 45.1]
n=10 
[13.7%] [6.8 - 23.8]
Ethanol use n=14 
[56.0%] [34.9 - 75.6]
n=20 
[27.4%] [17.6 - 39.1]
CI = confidence interval
FIGURE 1 - The predominant central nervous system diseases 
diagnosed and reported* in the elderly sample population 
(n=135) (A). Pharmacological classes of drugs acting in the 
CNS, used by the elderly sample population (n=146) (B). * 
Each patient may present with more than one disease and use 
more than one drug.
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TABLE II - Potential drug-drug interactions, based on reported prescribed medications in the elderly sample population of (n=40)
Interaction Intensity Possible effects n (%)
Tranylcypromine - 
Amitriptyline
Contraindicated Neurotoxicity, seizures, or 
serotonin syndrome
1 (2.5) 
Amitriptyline - Clonidine Severe Subtherapeutical effect 1 (2.5)
Amitriptyline – Haloperidol Severe
Amitriptyline - Sotalol 
Hydrochloride
Cardiotoxicity effect  2 (5.0) 
Amitriptyline - Fluoxetine Severe Tricyclic antidepressant 
toxicity and an increased risk of 
cardiotoxicity 
2 (5.0) 
Primidone - Flunitrazepam Severe Additive respiratory depression 1 (2.5) 
Fluoxetine - Aspirin 
Fluoxetine - Diclofenac
Fluoxetine - Ibuprofen
Sertraline - Aspirin
Sertraline - Diclofenac Severe Increased risk of bleeding 11 (27.5)
Alprazolam - Cimetidine Toxicity
Alprazolam - Fluoxetine Increased risk of alprazolam 
toxicity 
Alprazolam - Imipramine Increased imipramine plasma 
concentrations
Alprazolam - Omeprazol Benzodiazepine toxicity 
Amitriptyline - Cimetidine Amitriptyline toxicity 
Fluoxetine - Metoprolol Increased risk of metoprolol 
adverse effects 
Midazolam Maleate - 
Omeprazol
Benzodiazepine toxicity 
Phenytoin - Omeprazol Increased risk of phenytoin 
toxicity 
Sertraline - Carbamazepine Increased risk of 
carbamazepine toxicity 
Valproate Sodium - Aspirin Moderate Increased free valproic acid 
concentrations
12 (30.0)
Sertraline - Alprazolam Moderate Increased risk of psychomotor 
impairment and sedation
1 (2.5) 
Phenytoin - Simvastatin Moderate Loss of simvastatin efficacy 1 (2.5) 
Carbamazepine - Simvastatin Moderate Reduced simvastatin exposure 1 (2.5) 
Carbamazepine - Phenobarbital Moderate Subtherapeutical effect 1 (2.5) 
Sertraline - b-Blockers Moderate Increased risk of chest pain 1 (2.5) 
Tranylcypromine - Metformin Moderate Excessive hypoglycemia, CNS 
depression, and seizures
1 (2.5) 
Flunarizine - b-Blockers Moderate Hypotension, bradycardia, and 
AV conduction disturbances
1 (2.5) 
Amitriptyline - Diazepam Moderate Psychomotor deficits 1 (2.5) 
Ergotamine Tartrate - 
b-Blockers
Moderate Peripheral ischemia 1 (2.5) 
Carbamazepine - 
Hydrochlorothiazide
Moderate Hyponatremia 1 (2.5)
Potential interactions of central nervous system drugs used in the elderly population 231
represented 12 (9.6%) and were not of clinical importance.
Regarding the regular consumption of ethanol with 
CNS drugs in the elderly, we identified twenty poten-
tially moderate drug-ethanol interactions among those 
individuals who consume alcohol, resulting in symptoms 
of enhanced depression and sedation and impairment of 
motor skills. These interactions occurred mainly with 
benzodiazepines and tricyclic antidepressants (Table III). 
Although many elderly smoke tobacco or have 
smoked it in the past, only two of the drugs used within the 
population, alprazolam and imipramine, presented risks 
of interaction with tobacco, which may decrease serum 
concentrations of the CNS drugs. We found that 8 (6.4%) 
of the reported CNS-acting drugs could interact with ca-
ffeine, but all of these potential interactions were classified 
as having minor severity, as caffeine use could only reduce 
the sedative and the anxiolytic effects of the drugs.
DISCUSSION
In the last several decades, the use of psychotropic 
drugs has increased in many countries. This increase has 
been attributed to an increase in the diagnosis of psychia-
tric disorders within the population, the introduction of 
new drugs on the pharmaceutical market, and to new 
therapeutic indications for the already existing CNS drugs 
(Barg et al., 2006).
Similarly to other previously published studies, the 
majority of interviewed elderly who use CNS-acting drugs 
were female, possibly due to the fact that CNS drug use 
is higher amongst women simply because women more 
often seek help from the health services. In addition, accor-
ding to the Institute of Brazilian Geography and Statistics 
(IBGE), the women living in Porto Alegre outnumber the 
men (Coelho, Marcopito, Castelo, 2004; Flores, Mengue, 
2005; IBGE, 2003). On the other hand, men reported more 
alcohol and tobacco use than women (Table I).
In addition to the pharmacokinetic and pharmaco-
dynamic peculiarities of drug in elderly patients, the high 
cost of taken drugs coupled with the fact that elderly pa-
tients are often prescribed several drugs for their various 
medical conditions, and it can lead some patients to take 
fewer drugs than their prescribed treatment regimen. On 
the other hand, it is also common to find that medical 
professionals have prescribed the elderly with inadequate 
dosage, incorrect indications, potential drug interactions 
and/or unsuitable associations, and little or no therapeutic 
value medications (Liu, Christensen, 2002). 
According to our survey, drugs that act in the CNS 
for diseases such as depression, sleep-disturbances and 
anxiety were commonly prescribed in our sample popu-
lation (Figure 1A). Around half (50.7%) of the elderly we 
interviewed were taking anxiolytic/hypnotics, the most 
commonly-prescribed drug in our sample population of 
CNS drug users. International guidelines suggest that ben-
zodiazepines should not be used uninterruptedly for more 
than two to four weeks, and that a stoppage interval at the 
end of this period should be applied, before administration 
restarting . The use of these drugs for long periods of time 
can induce potentially dangerous side-effects, such as falls, 
memory disease and accidents (Barg et al., 2006).
Respecting to the potentially severe DDIs, the 
contraindicated use of amitriptyline-tranylcypromine 
was identified, which can result in serious consequences 
TABLE III - Potential ethanol-drug interactions, based on reported prescribed medications and regular alcohol use in the elderly 
sample population (n=20)
Interaction
(Drug + Ethanol)
Possible effects Intensity n (%) 
Alprazolam
Chlordiazepoxide
Diazepam
Flunitrazepam
Lorazepam
Increased sedation Moderate 13 (65.0) 
Amitriptyline Enhanced CNS depression and impairment of motor 
skills
Moderate 3 (15.0)
Phenytoin Decreased phenytoin serum concentrations, 
increased seizure potential, and additive CNS 
depressant effects
Moderate 1 (5.0)
Sertraline Increased risk of impairment of mental and motor 
skills
Moderate 1 (5.0)
Imipramine
Chlomipramine
Enhanced drowsiness; impairment of motor skills. Moderate 2 (10.0)
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(Table II) including neurotoxicity that can produce a poi-
sonous or lethal effect on the nervous system. Frequently, 
neurological complications are also observed, such as 
mental alterations, cerebral ataxia, convulsions, and peri-
pheral neuropathies. It is surprising to find that tranylcy-
promine prescriptions, at least in our sample population, 
are not being more carefully given and folowed-up for the 
treatment of psychiatric ailments.
Serotonin syndrome, characterized by symptoms 
of hallucination, muscle rigidity, lethargy, hypotension, 
tachycardia, and respiratory insufficiency, is another se-
rious adverse reaction reported with serotoninergic drug 
use. Thus, when amitriptyline and tranylcypromine are 
co-prescribed, adverse events must be closely monitored, 
particularly in elderly patients (Araujo, Nery-Fernandes, 
Quarantini; 2006; Karunatilake, Buckley, 2006; Kozian, 
2005; Mackay, Dunn, Mann, 1999).
Studies from different countries have been publi-
shed reporting a pronounced increase in polypharmacy 
as patients age, which highlights the need for prescribers 
and pharmacists to be aware of drug interactions, parti-
cularly in elderly (Astrand et al., 2007; Johnell, Klarin, 
2007; Kotirum S et al., 2007; Thijs et al., 2006). It has 
been estimated that patients taking two drugs face a 
13% risk of drug interactions, rising to 38% when taking 
four drugs, and to 82% if seven or more drugs are given 
simultaneously (Goldberg et al., 1996). Furthermore, 
prescription of potentially inappropriate medications to 
older people is highly prevalent in the United States and 
Europe, and inappropriate prescribing is associated with 
increased risk for adverse drug events (Gallagher, Barry, 
O’Mahony, 2007).
As previously described in several studies, other 
commonly-used drugs such as fluoxetine, alprazolam, and 
sertraline can lead to interactions of a severe or moderate 
intensity. The effects of these drug interactions can bring 
serious consequences within a short period of time and 
serious cases of toxicity can appear, leading to additional 
health problems in the elderly population (Coelho, Mar-
copito, Castelo, 2004).
In this study, we identified 20 moderate drug-ethanol 
interactions, which can result in decreased drug serum 
concentrations, increased seizure potential, and additive 
CNS depressant effects; therefore, patients who are pres-
cribed ethanol-interacting drugs should be more strongly 
dissuaded from ethanol use by their physicians and phar-
macists. Ethanol can interact, pharmacokinetically and 
pharmacologically with some CNS drugs and, in many 
cases, can increase their action, because both use the liver 
as metabolic tract. Alternatively, ethanol can suppress the 
action of other CNS medications because it competes with 
the drugs. Ethanol is a central nervous system depressant 
that potentiates gamma-aminobutyric acid (GABA) ac-
tion and, at the same time, inhibits the glutamate action 
in N-methyl-D-aspartate (NMDA) receptors, causing 
sleepiness, irritability, and/or euphoria. Acute ingestion of 
ethanol in patients taking phenytoin reduces its breakdown 
because both drugs compete in the metabolic system. The 
concomitant ingestion of alcohol with paroxetine can have 
additive effects, such as sedation and alteration of motor 
abilities (Linnoila, Mattila, Kitchell, 1979). 
Only two drugs, alprazolam and imipramine, were 
identified as interacting with tobacco; such interaction re-
sults in the reduction of both drugs concentration. Studies 
regarding this interaction have shown that the liberation 
of a number of substances (carbon monoxide, hydrogen 
cyanide, aldehydes, benzopyrenes, nicotine, pesticides, 
and nitrosamines) from tobacco used in cigarette form, 
can lead to a number of pharmacodynamic and pharma-
cokinetic interactions. Thus, some drugs have their effects 
diminished due to the hepatic metabolism induced by 
tobacco (Balbani, Montovani, 2005; Ferigolo et al., 2004).
Few studies are published regarding the implications 
of alcohol and tobacco use and food consumption together 
with drug therapy. The interactions with alcohol or tobacco 
may be unavoidable in certain cases, since the patients 
may not want to quit drinking and/or smoking; however, 
alcohol and tobacco-interacting drugs should be prescribed 
with caution, if no better alternative therapy is available 
for the patient’s disease. It is important to highlight that the 
need for clinical information, which should be provided 
and interpreted by the prescribing physician and pharma-
cist, is essential for the elderly patients.
Out of the potential drug/caffeine interactions ob-
served in this study, all were potentially minor as they 
reduce anxiolytic and sedative effects. Caffeine is an alkali 
CNS stimulant that is naturally present in some plants and 
belongs to the group of methyl-xantines. When managed 
separately, it does not have significant analgesic activity; 
however, when taken in association with other drugs, 
significant consequences may occur. Caffeine opposes the 
hypnotic and sedative effects of barbiturates, inducing an 
increased necessity for these drugs, which in turn facili-
tates dependency (Alavijeh et al., 2005).
CONCLUSION
The results presented in this study demonstrate that 
the risk of potential drug interactions was strongly correla-
ted with the concomitant use of multiple drugs, alcohol and 
tobacco among the elderly population taking psychotropic 
medications. Elderly patients should be better educated by 
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the physician on potential interactions with prescription 
drugs that are commonly involved in ‘severe` drug-drug, 
drug-ethanol, drug-tobacco, and drug-caffeine interac-
tions, and prescribed drug combinations should be further 
analyzed by a clinical pharmacist prior to drug dispensing. 
Furthermore, elderly patients should be closely monitored 
for adverse drug reactions and potential pharmacological 
interactions, particularly with drugs that act in the CNS. 
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